Biogen (NASDAQ:BIIB) Price Target Raised to $236.00

Biogen (NASDAQ:BIIB) had its price objective increased by Mizuho from $207.00 to $236.00 in a report issued on Tuesday, Marketbeat Ratings reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other equities analysts also recently commented on BIIB. Royal Bank Of Canada increased their target price on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research report on Monday. Wolfe Research set a $231.00 price objective on Biogen in a report on Monday. Guggenheim raised their price objective on Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday. Oppenheimer upped their target price on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, January 30th. Finally, Stifel Nicolaus lifted their price target on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $205.84.

Biogen Price Performance

Shares of BIIB opened at $195.50 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm has a market cap of $28.69 billion, a PE ratio of 22.19, a PEG ratio of 1.52 and a beta of 0.16. The firm’s 50 day moving average price is $177.92 and its 200 day moving average price is $158.38. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, research analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Biogen

Several hedge funds have recently made changes to their positions in BIIB. WPG Advisers LLC increased its stake in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter worth approximately $30,000. Root Financial Partners LLC increased its position in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. GoalVest Advisory LLC acquired a new position in shares of Biogen in the fourth quarter valued at $35,000. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Biogen in the second quarter valued at $25,000. Institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and raised FY‑2026 guidance — Biogen reported EPS and revenue above consensus and set FY‑2026 EPS guidance of $15.25–$16.25, which underpins improved earnings visibility and has been a major catalyst for analyst upgrades. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The subcutaneous formulation (lecanemab) received a priority review designation, which could expand commercial reach and margins if approved. This boosts upside to the Alzheimer’s franchise over the medium term. Article Title
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms lifted targets (Mizuho to $236, Citi, RBC, Canaccord and others raised targets), supporting further upside expectations and trading interest. Article Title
• Positive Sentiment: Institutional accumulation — Major holders (Vanguard, State Street, Geode, Norges Bank, Invesco) either added or maintain large stakes, indicating continued institutional conviction and providing bid support.
• Neutral Sentiment: Board chair transition — Caroline Dorsa is retiring and Dr. Maria C. Freire was elected chair. Governance change reduces uncertainty about succession but is unlikely to be an immediate earnings driver. Article Title
• Neutral Sentiment: Short‑interest data appears unreliable — Published short‑interest entries show zero shares / NaN changes and are internally inconsistent; there’s no clear sign of short‑covering driving today’s move.
• Negative Sentiment: Insider sale — Director/officer Priya Singhal sold 2,660 shares recently (filing shows sales around the $180–$200 range). Insider selling can raise short‑term concern about timing or valuation. Article Title
• Negative Sentiment: Ongoing franchise pressure and execution risk — Analysts and commentary note MS franchise pressures and execution risk around scaling Leqembi access/commercialization, which could cap upside if execution slips. Article Title

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.